.png){kind=icon}
.png){kind=icon}
Return
Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment
.png){kind=icon}
PRE
AI
N
L
D
M
DOI：10.1002/bcp.70675.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Cutaneous leishmaniasis (CL), a neglected infectious disease caused by the intracellular protozoan parasite Leishmania, affects over one million people annually. The type and magnitude of the inflammatory response elicited during infection lead to skin-specific immunopathology, resulting in the clinical manifestations of CL. Systemic antileishmanial drugs are the main control measure; however, these are highly toxic, of long duration, and difficult to access for affected populations. New drugs and optimized regimens are urgently needed. Despite the known participation of immune responses in the pathology of CL, preclinical drug evaluations target parasite elimination as the efficacy measure. This overlooks the potential of host immune responses to influence therapeutic success.
Keywords:
cutaneous leishmaniasis
inflammation
Leishmania
meglumine antimoniate
pharmacodynamics
pharmacokinetics
Journal
IF:
3
Papers:
8.5K
Citations:
1.8W
Organization
Cited Papers